181 related articles for article (PubMed ID: 25564201)
1. The breast cancer immunophenotype of TP53-p.R337H carriers is different from that observed among other pathogenic TP53 mutation carriers.
Fitarelli-Kiehl M; Giacomazzi J; Santos-Silva P; Graudenz MS; Palmero EI; Michelli RA; Achatz MI; de Toledo Osório CA; de Faria Ferraz VE; Picanço CG; Ashton-Prolla P
Fam Cancer; 2015 Jun; 14(2):333-6. PubMed ID: 25564201
[TBL] [Abstract][Full Text] [Related]
2. Li-Fraumeni and Li-Fraumeni-like syndrome among children diagnosed with pediatric cancer in Southern Brazil.
Giacomazzi J; Selistre SG; Rossi C; Alemar B; Santos-Silva P; Pereira FS; Netto CB; Cossio SL; Roth DE; Brunetto AL; Zagonel-Oliveira M; Martel-Planche G; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
Cancer; 2013 Dec; 119(24):4341-9. PubMed ID: 24122735
[TBL] [Abstract][Full Text] [Related]
3. Association of the germline TP53 R337H mutation with breast cancer in southern Brazil.
Assumpção JG; Seidinger AL; Mastellaro MJ; Ribeiro RC; Zambetti GP; Ganti R; Srivastava K; Shurtleff S; Pei D; Zeferino LC; Dufloth RM; Brandalise SR; Yunes JA
BMC Cancer; 2008 Dec; 8():357. PubMed ID: 19046423
[TBL] [Abstract][Full Text] [Related]
4. Breast Cancer Phenotype Associated With Li-Fraumeni Syndrome: A Brazilian Cohort Enriched by
Sandoval RL; Polidorio N; Leite ACR; Cartaxo M; Pisani JP; Quirino CV; Cezana L; Pereira NG; Pereira AAL; Rossi BM; Achatz MI
Front Oncol; 2022; 12():836937. PubMed ID: 35371985
[TBL] [Abstract][Full Text] [Related]
5. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil.
Palmero EI; Schüler-Faccini L; Caleffi M; Achatz MI; Olivier M; Martel-Planche G; Marcel V; Aguiar E; Giacomazzi J; Ewald IP; Giugliani R; Hainaut P; Ashton-Prolla P
Cancer Lett; 2008 Mar; 261(1):21-5. PubMed ID: 18248785
[TBL] [Abstract][Full Text] [Related]
6. The Brazilian founder mutation TP53 p.R337H is uncommon in Portuguese women diagnosed with breast cancer.
Giacomazzi J; Correia RL; Palmero EI; Gaspar JF; Almeida M; Portela C; Camey SA; Monteiro A; Pinheiro M; Peixoto A; Teixeira MR; Reis RM; Ashton-Prolla P
Breast J; 2014; 20(5):534-6. PubMed ID: 25052705
[TBL] [Abstract][Full Text] [Related]
7. p53 signaling pathway polymorphisms, cancer risk and tumor phenotype in TP53 R337H mutation carriers.
Macedo GS; Vieira IA; Vianna FSL; Alemar B; Giacomazzi J; Brandalize APC; Caleffi M; Volc SM; de Campos Reis Galvão H; Palmero EI; Achatz MI; Ashton-Prolla P
Fam Cancer; 2018 Apr; 17(2):269-274. PubMed ID: 28756477
[TBL] [Abstract][Full Text] [Related]
8. A TP53 founder mutation, p.R337H, is associated with phyllodes breast tumors in Brazil.
Giacomazzi J; Koehler-Santos P; Palmero EI; Graudenz MS; Rivero LF; Lima E; Pütten AC; Hainaut P; Camey SA; Michelli RD; Neto CS; Fitarelli-Kiehl M; Geyer G; Meurer L; Geiger A; Azevedo MB; da Silva VD; Ashton-Prolla P
Virchows Arch; 2013 Jul; 463(1):17-22. PubMed ID: 23794094
[TBL] [Abstract][Full Text] [Related]
9. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of an inherited cancer predisposition syndrome associated with the germ line TP53 R337H mutation in Paraguay.
Legal EF; Ascurra M; Custódio G; Ayala HL; Monteiro M; Vega C; Fernández-Nestosa MJ; Vega S; Sade ER; Coelho IM; Ribeiro EM; Cavalli IJ; Figueiredo BC
Cancer Epidemiol; 2015 Apr; 39(2):166-9. PubMed ID: 25736369
[TBL] [Abstract][Full Text] [Related]
11. Increased oxidative damage in carriers of the germline TP53 p.R337H mutation.
Macedo GS; Lisbôa da Motta L; Giacomazzi J; Netto CB; Manfredini V; Vanzin CS; Vargas CR; Hainaut P; Klamt F; Ashton-Prolla P
PLoS One; 2012; 7(10):e47010. PubMed ID: 23056559
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of the TP53 p.R337H mutation in breast cancer patients in Brazil.
Giacomazzi J; Graudenz MS; Osorio CA; Koehler-Santos P; Palmero EI; Zagonel-Oliveira M; Michelli RA; Scapulatempo Neto C; Fernandes GC; Achatz MI; Martel-Planche G; Soares FA; Caleffi M; Goldim JR; Hainaut P; Camey SA; Ashton-Prolla P
PLoS One; 2014; 9(6):e99893. PubMed ID: 24936644
[TBL] [Abstract][Full Text] [Related]
13. Contribution of the TP53 R337H mutation to the cancer burden in southern Brazil: Insights from the study of 55 families of children with adrenocortical tumors.
Mastellaro MJ; Seidinger AL; Kang G; Abrahão R; Miranda ECM; Pounds SB; Cardinalli IA; Aguiar SS; Figueiredo BC; Rodriguez-Galindo C; Brandalise SR; Yunes JA; Barros-Filho AA; Ribeiro RC
Cancer; 2017 Aug; 123(16):3150-3158. PubMed ID: 28387921
[TBL] [Abstract][Full Text] [Related]
14. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
Packwood K; Martland G; Sommerlad M; Shaw E; Moutasim K; Thomas G; Bateman AC; Jones L; Haywood L; Evans DG; Birch JM; Alsalmi OA; Henderson A; Poplawski N; Eccles DM
J Pathol Clin Res; 2019 Jul; 5(3):189-198. PubMed ID: 31041842
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of germline mutations in the TP53 gene in patients with early-onset breast cancer in the Mexican population.
Gallardo-Alvarado LN; Tusié-Luna MT; Tussié-Luna MI; Díaz-Chávez J; Segura YX; Bargallo-Rocha E; Villarreal C; Herrera-Montalvo LA; Herrera-Medina EM; Cantu-de Leon DF
BMC Cancer; 2019 Feb; 19(1):118. PubMed ID: 30709381
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li-Fraumeni syndrome).
Petry V; Bonadio RC; Cagnacci AQC; Senna LAL; Campos RDNG; Cotti GC; Hoff PM; Fragoso MCBV; Estevez-Diz MDP
Fam Cancer; 2020 Jan; 19(1):47-53. PubMed ID: 31748977
[TBL] [Abstract][Full Text] [Related]
18. Frequency of Thyroid Carcinoma in Brazilian TP53 p.R337H Carriers With Li Fraumeni Syndrome.
Formiga MNDC; de Andrade KC; Kowalski LP; Achatz MI
JAMA Oncol; 2017 Oct; 3(10):1400-1402. PubMed ID: 28114597
[TBL] [Abstract][Full Text] [Related]
19. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.
Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I
Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373
[TBL] [Abstract][Full Text] [Related]
20. Germline TP53 mutation spectrum in Sudanese premenopausal breast cancer patients: correlations with reproductive factors.
Aceto GM; Awadelkarim KD; Di Nicola M; Moscatello C; Pantalone MR; Verginelli F; Elwali NE; Mariani-Costantini R
Breast Cancer Res Treat; 2019 Jun; 175(2):479-485. PubMed ID: 30796655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
